In the dynamic landscape of biopharmaceutical innovation, the traditional focus on groundbreaking scientific discovery is increasingly being complemented by a rigorous examination of operational viability. As licensing deals become a cornerstone of pipeline growth and strategic partnerships, the evidence of robust Chemistry, Manufacturing, and Controls (CMC) readiness is emerging as a decisive factor in determining an asset’s true value and fostering unwavering confidence for potential investors and collaborators. This shift underscores a more mature and operational approach to biopharma licensing, where the ability to reliably transfer, scale, and supply a drug product without compromising its commercial potential is paramount.
The Evolving Biopharma Dealmaking Landscape
Biopharmaceutical companies are actively seeking external innovation to fuel their growth, a trend that has significantly amplified the importance of licensing agreements. These agreements, whether in-licensing (acquiring rights to an external asset) or out-licensing (granting rights to an asset), are complex transactions that extend far beyond the initial scientific validation. They encompass a meticulous process involving asset valuation, partner identification, data-room preparation, comprehensive due diligence, intricate negotiation, and the finalization of contracts. The subsequent journey through development, regulatory submissions, manufacturing, and eventual market launch means that decisions made during the pre-signing phase can profoundly influence costs, timelines, and the resilience of the supply chain for years to come.
The Asia-Pacific region, particularly China, has become a pivotal hub in this global licensing network. Its emergence as a significant source of innovative assets has reshaped international dealmaking. Data from GlobalData’s 2026 conference analysis revealed a striking trend: by 2025, nearly 50% of in-licensing agreements by US biopharma companies involved innovative drugs originating from China. This momentum continued into 2026, as evidenced by high-profile collaborations announced at the JP Morgan Healthcare Conference. AbbVie secured a licensing agreement valued at an impressive $5.6 billion for RemeGen’s Phase II bispecific antibody, RC148. Concurrently, Novartis entered into a collaboration exceeding $1.6 billion with SciNeuro Pharmaceuticals, focusing on novel candidates for Alzheimer’s disease.
The allure of partnering with companies in the Asia-Pacific region extends beyond potential cost efficiencies in development. GlobalData’s research also highlights the advantages of accelerated clinical trials, enhanced research capabilities, and access to a deeper pipeline of differentiated therapeutic candidates. This outbound licensing activity is equally significant, with GSK’s substantial $12.5 billion agreement with Jiangsu Hengrui in 2025 serving as a prime example of the value generated through these cross-border collaborations.
The Ascendancy of CMC Due Diligence and the Role of CDMOs
These increasingly frequent and complex cross-border licensing deals place a heightened emphasis on rigorous CMC due diligence. Prospective licensees face the critical task of verifying whether a promising clinical product can be consistently reproduced at the required commercial scale. Furthermore, they must ascertain if the existing data is sufficient to support regulatory filings in their target markets and if the accumulated manufacturing knowledge can be seamlessly transferred across different companies, facilities, and geographical locations. This is where the expertise of a Contract Development and Manufacturing Organization (CDMO) becomes indispensable. A CDMO with intimate knowledge of the asset’s manufacturing processes can empower potential partners to rigorously test these assumptions against the underlying scientific, technical, and regulatory evidence.
Deconstructing Asset Valuation: Beyond the Science
Traditional financial models for valuing biopharmaceutical assets typically incorporate revenue forecasts, projected development expenditures, patent exclusivity periods, competitive positioning, and the inherent probability of achieving regulatory and commercial success. However, the foundational assumptions underpinning these projections can be significantly weakened by inadequate manufacturing strategies. Conversely, tangible evidence of process robustness, achievable cost of goods, scalable manufacturing capacity, successful technology transfer, and a clear path to regulatory compliance can substantially bolster the confidence in the assumptions that drive asset valuation.
CMC due diligence is a multi-faceted investigation. It meticulously examines the depth of understanding of the manufacturing process and its scalability. It assesses the suitability and validation of analytical methods, scrutinizes stability data to ensure adequate shelf-life, and verifies that drug substance and drug product specifications are scientifically justified. Beyond these core elements, the diligence process delves into critical areas such as the characterization and control of impurities and degradation products, the efficacy of quality management systems, the historical batch records, and the outcomes of previous interactions with regulatory authorities. These inquiries are not merely about identifying manufacturing risks; they are strategic inputs that directly influence the technical, regulatory, and financial viability of an asset.
An immature manufacturing process can necessitate extensive additional development before pivotal clinical trials can commence, potentially leading to significant delays and increased costs. Incomplete stability studies can severely constrain the ability to plan for long-term supply chains. Moreover, the use of inadequately validated analytical methods can complicate the demonstration of product comparability following any manufacturing changes, a common occurrence in the lifecycle of a drug. Perhaps most critically, unrealistic assumptions regarding the cost of goods can undermine the entire commercial case for an otherwise promising therapeutic.
A recent webinar hosted by Thermo Fisher Scientific illuminated these critical aspects, advocating for an "audit-ready CMC package." This package should feature traceable, consistent data, irrefutable evidence of process robustness, proactive planning for early-stage scale-up, and a transparent narrative clearly delineating what is known, what uncertainties remain, and the strategic roadmap for addressing any identified gaps. Such a comprehensive approach enables prospective partners to effectively distinguish between manageable development challenges and fundamental risks that could jeopardize a program or necessitate a significant downward adjustment in valuation. It also solidifies confidence in assumptions related to scalability, cost, capacity, technology transfer readiness, and the overall pathway to commercialization.
Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services at Thermo Fisher Scientific, aptly describes CMC due diligence as an intrinsic component of asset valuation. He states, "The CMC package and due diligence act as a strategic gate to evaluate a variety of factors and the value of the asset."
The Strategic Advantage of CDMO Partnership
A CDMO possessing extensive experience across the entire spectrum of drug development, technology transfer, regulatory submissions, and commercial manufacturing can contribute significant value throughout the entire transaction lifecycle. Prior to deal execution, a CDMO can assist in the meticulous construction of a licensing-ready CMC package, proactively identify potential gaps, and bolster the process and scale-up readiness of the asset. During the due diligence phase, their expertise is invaluable in supporting technical assessments, conducting audits, performing gap analyses, evaluating manufacturing feasibility, refining cost and capacity projections, and providing critical insights into regulatory considerations. Post-agreement, the CDMO is instrumental in translating these assessments into tangible remediation efforts, successful technology transfers, effective scale-up strategies, and robust regulatory support, ultimately ensuring a seamless transition to commercial supply.
Thermo Fisher Scientific shared compelling examples from their webinar illustrating the profound impact of CDMO involvement. They detailed their support for a low-dose oncology tablet developed by an Asian biotech, encompassing drug product development, technology transfer, clinical manufacturing, and subsequent scale-up. This work was subsequently subjected to rigorous audits and gap analyses by multiple prospective partners during their diligence processes. Ultimately, a global biopharmaceutical company acquired the asset in a transaction valued at over $1 billion, a clear testament to how meticulous CMC execution can directly enhance transaction confidence and significantly amplify asset value.
Strategies for Maximizing Deal Success Through Proactive CMC Management
To optimize their negotiating position and enhance the likelihood of a successful licensing deal, companies must prioritize strengthening their CMC readiness before formal due diligence commences. This proactive approach shifts CMC from being solely a risk mitigation exercise to a strategic enabler of value creation. The cornerstone of this preparation is the development of an "audit-ready CMC package." This comprehensive dossier consolidates all pertinent process knowledge, analytical methods, product specifications, stability data, and historical batch records into a coherent, traceable, and readily accessible format.
Crucially, this package should clearly differentiate between issues that have been definitively resolved and those that represent ongoing development work. It must articulate how critical quality attributes (CQAs) are meticulously controlled, provide concrete evidence supporting process robustness, and outline a feasible strategy for transferring the manufacturing process to a new facility or manufacturing partner. Presenting these details transparently and early in the process empowers potential licensees to accurately assess the scope of remaining development work, thereby avoiding the assumption that every identified gap signifies a fundamental, insurmountable weakness.
Furthermore, licensing teams must meticulously account for potential challenges related to equipment differences, the sourcing of raw materials, the stringent requirements for demonstrating product comparability, the availability of manufacturing capacity, and the realistic timelines associated with completing necessary technical work. Clear lines of responsibility for these activities should be established and agreed upon during the negotiation phase, delineating which tasks must be finalized before the deal signing and which can be undertaken as part of the post-agreement collaboration.
An experienced CDMO can significantly enhance this preparatory phase by rigorously testing assumptions related to cost, timelines, process performance, and supply chain reliability. This independent scrutiny serves to expose potential weaknesses before they escalate into contentious negotiating points, thereby providing both parties with a more credible and data-driven foundation for valuation and risk allocation. Post-signing, the same trusted CDMO partner can then effectively bridge the gap between assessment and execution, transforming diligence findings into concrete remediation, seamless technology transfer, and successful scale-up activities.
Anil Kane emphasizes the essential preparation: "Build a licensing-ready data package, including well-organized, audit-ready documentation." He further stresses the paramount importance of transparency, advocating for development, manufacturing, and analytical information that is traceable, easily accessible, and presented with unwavering consistency.
While clinical performance will undoubtedly remain the primary determinant of an asset’s future prospects, a well-defined and robust pathway from development to commercial supply serves to significantly reduce uncertainty, bolster confidence in execution, and facilitate the negotiation of terms that accurately reflect the asset’s true intrinsic potential. In conclusion, the strategic integration of CMC readiness and the judicious leveraging of CDMO expertise are no longer optional considerations but essential components for enhancing asset value and effectively mitigating risk in the increasingly complex world of biopharmaceutical licensing.
About the Author
